Scientists at the Institut Pasteur and Inserm developed a triple therapy that made cancerous B-cells die in a way called necroptosis, which activated a strong immune response against leukemia in preclinical models[1][5][6]. This combination of three drugs, already approved for clinical use, reprogrammed malignant cells to release immune cell-attracting signals that subsequently eliminated the leukemia altogether[1][6]. Necroptosis differs from normal apoptosis in that it induces immune activation, increasing the body's ability to fight tumor cells[1]. Researchers have used advanced imaging techniques to monitor the interaction of immune cells with cancer cells in real time, confirming the effectiveness of this therapy[1]. This approach represents a new direction in immunotherapy, particularly for blood tumors such as leukemias and lymphomas affecting B-cells[1]. The results of the study were published in the journal Science Advances and suggest the potential of this therapy for future clinical applications[1].